Synaptogenix, Inc. SNPX
We take great care to ensure that the data presented and summarized in this overview for Synaptogenix, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SNPX
View allLatest Institutional Activity in SNPX
Top Purchases
Top Sells
About SNPX
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.
Insider Transactions at SNPX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2025
|
Alan J Tuchman Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,726
-30.63%
|
$12,082
$7.85 P/Share
|
|
Jun 30
2025
|
Alan J Tuchman Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,315
+43.37%
|
-
|
|
Jun 30
2025
|
Bruce Bernstein Director |
SELL
Payment of exercise price or tax liability
|
Direct |
9,863
-38.29%
|
$69,041
$7.85 P/Share
|
|
Jun 30
2025
|
Bruce Bernstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
24,657
+48.91%
|
-
|
|
Jun 30
2025
|
Jonathan Schechter Director |
SELL
Payment of exercise price or tax liability
|
Direct |
8,630
-38.08%
|
$60,410
$7.85 P/Share
|
|
Jun 30
2025
|
Jonathan Schechter Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,575
+48.77%
|
-
|
|
Jun 30
2025
|
Joshua Silverman Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
16,768
-38.59%
|
$117,376
$7.85 P/Share
|
|
Jun 30
2025
|
Joshua Silverman Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
41,919
+49.1%
|
-
|
|
Jun 30
2025
|
Robert Weinstein Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,164
-36.83%
|
$43,148
$7.85 P/Share
|
|
Jun 30
2025
|
Robert Weinstein Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,410
+47.93%
|
-
|
|
Jun 30
2025
|
William S. Singer Director |
SELL
Payment of exercise price or tax liability
|
Direct |
6,164
-36.84%
|
$43,148
$7.85 P/Share
|
|
Jun 30
2025
|
William S. Singer Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,410
+47.95%
|
-
|
|
Dec 16
2022
|
Alan J Tuchman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
27,000
-45.0%
|
$27,000
$1.17 P/Share
|
|
Dec 16
2022
|
Bruce Bernstein Director |
SELL
Open market or private sale
|
Direct |
22,500
-44.93%
|
$22,500
$1.17 P/Share
|
|
Dec 16
2022
|
Daniel L. Alkon President and CSO |
SELL
Open market or private sale
|
Direct |
19,688
-35.64%
|
$19,688
$1.17 P/Share
|
|
Dec 16
2022
|
Jonathan Schechter Director |
SELL
Open market or private sale
|
Direct |
20,250
-41.54%
|
$20,250
$1.17 P/Share
|
|
Dec 16
2022
|
Joshua Silverman Executive Chairman |
SELL
Open market or private sale
|
Direct |
19,012
-33.21%
|
$19,012
$1.17 P/Share
|
|
Dec 16
2022
|
Robert Weinstein Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
27,000
-44.85%
|
$27,000
$1.17 P/Share
|
|
Dec 16
2022
|
William S. Singer Director |
SELL
Open market or private sale
|
Direct |
27,000
-45.0%
|
$27,000
$1.17 P/Share
|
|
Jul 13
2021
|
Joshua Silverman Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+46.15%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 123K shares |
|---|
| Payment of exercise price or tax liability | 49.3K shares |
|---|